title: Clinical effect of Maixuekang Capsule (脉血康胶囊) on long-term prognosis in patients with acute coronary syndrome after percutaneous coronary intervention.
abstract: OBJECTIVE
  To study the changes of adenosine diphosphate (ADP)-induced platelet aggregation rate, and evaluate the effects of Maixuekang Capsule (, MKC) on platelet aggregation rate and long-term prognosis of patients with acute coronary syndrome after percutaneous coronary intervention (PCI).
  
  
  METHODS
  A total of 236 patients with acute coronary syndrome, who received successful PCI, were randomly assigned to a trial group (116 cases) and a control group (120 cases) according to random numbers; treatment allocation occurred when the participants met the inclusion criteria and signed the informed consent forms. In the trial group, the patients were treated with MKC combined with routine medication, and in the control group the patients were treated with routine medication. The therapeutic course for the two groups was 12 months and the follow-up was 12 months. The levels of ADP-induced platelet aggregation rate and serum high-sensitive C-reactive protein (hs-CRP) were determined before PCI, 12 h and 30 days after PCI. In the meantime, the incidence of cardio-/cerebrovascular events was recorded during the 12-month follow-up.
  
  
  RESULTS
  Compared with before PCI, the levels of ADP-induced platelet aggregation rate and serum hs-CRP were significantly higher at 12 h after PCI (P<0.05). They were significantly reduced after 30-day-treatment of MKC, showing statistical differences when compared with those in the control group (P<0.05). During the 12-month follow-up, the incidence of cardio-/cerebrovascular events was significantly lower in the trial group than in the control group (6.9% vs. 12.5%, P<0.01).
  
  
  CONCLUSIONS
  ADP-induced platelet aggregation function was significantly elevated after PCI. MKC improved the prognosis of patients with acute coronary syndrome, possibly through inhibiting the platelet aggregation, fighting against inflammation, and protecting the vascular endothelial function.
authors: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
authors: Chang-jiang
authors: CJ
authors: Ge
authors: Fei
authors: F
authors: Yuan
authors: Li-xia
authors: LX
authors: Feng
authors: Shu-zheng
authors: SZ
authors: Lv
authors: Hong
authors: H
authors: Liu
authors: Xian-tao
authors: XT
authors: Song
authors: Xin
authors: X
authors: Chen
authors: Yong
authors: Y
authors: Huo
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000601:surgery*; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism; D002214:Capsules; D004365:Drugs, Chinese Herbal / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D062645:Percutaneous Coronary Intervention; D010974:Platelet Aggregation / Q000187:drug effects; D011379:Prognosis
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal; D000244:Adenosine Diphosphate; D002097:C-Reactive Protein